Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.
J Heart Lung Transplant. 2010 Sep;29(9):989-96. doi: 10.1016/j.healun.2010.05.001. Epub 2010 Jun 8.
Nearly all patients receiving heart transplantation (HTx) in Germany are now those listed in urgent status. In this study we review urgency-based allocation policy for HTx candidates with ventricular assist devices (VADs).
We retrospectively studied 345 adult candidates for de novo HTx. Group U (n = 160) comprised patients primarily listed in urgent status without VAD. Group VAD-45 (n = 167) comprised patients with intended bridging to HTx who survived >45 days after VAD implantation (after initial drop in survival rates). Among these patients, those who died of stroke or were awarded urgent status due to difficulties of coagulation management (thrombus formation, thromboembolism and bleeding) in the first year after VAD implantation were assigned to Group COAG (n = 36), and those who died or were awarded urgent status due to device-related infection in the same period were assigned to Group INF (n = 31). Actuarial survival rates were studied in each group.
Survival rates during support in Group VAD-45 were comparable to those during urgent status in Group U. Bridge-to-transplant rate was 63.9% in Group COAG and 58.1% in Group INF. The post-transplant 3-year survival rate of 85.3% in Group COAG was significantly higher than that in Group INF (46.8%, p < 0.01) and Group U (62.4%, p < 0.05).
Patients who have a VAD for >45 days should be awarded some priority for urgent HTx, which is currently prohibited in Germany. Patients listed in urgent status due to difficulties of coagulation management should be prioritized over those listed for device-related infection to make effective use of limited resources.
目前,在德国接受心脏移植(HTx)的几乎所有患者都属于紧急状态。本研究回顾了心室辅助装置(VAD)患者的紧急分配政策。
我们回顾性研究了 345 例接受新 HTx 的成年患者。U 组(n=160)包括主要列入紧急状态且未使用 VAD 的患者。VAD-45 组(n=167)包括计划桥接至 HTx 的患者,他们在 VAD 植入后存活超过 45 天(初始生存率下降后)。在这些患者中,由于 VAD 植入后第一年的凝血管理困难(血栓形成、血栓栓塞和出血)而死亡或因紧急状态而获得优先权的患者被分配到 COAG 组(n=36),而由于同期与设备相关的感染而死亡或获得紧急状态的患者被分配到 INF 组(n=31)。研究了每组的生存率。
VAD-45 组的支持期间生存率与 U 组的紧急状态期间生存率相当。COAG 组的桥接移植率为 63.9%,INF 组为 58.1%。COAG 组移植后 3 年的生存率为 85.3%,明显高于 INF 组(46.8%,p<0.01)和 U 组(62.4%,p<0.05)。
在德国目前禁止的情况下,对于使用 VAD 超过 45 天的患者,应给予紧急 HTx 的优先权。对于因凝血管理困难而列入紧急状态的患者,应优先考虑那些因设备相关感染而列入紧急状态的患者,以有效利用有限的资源。